Develops T cell therapies for cancer.
Mar 2026Revenue $3.95M/yrExpenses $17.2M/yr
No trendCash runway ≈ 1.2 years from Jun 2026
Figures by year
When will Marker Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $3.95M and expenses $17.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.55M | $16.4M | −$12.9M |
| Dec 2024 | $6.59M | $17.7M | −$11.1M |
| Dec 2023 | $3.31M | $17.9M | −$14.6M |
| Dec 2022 | $3.51M | $23.3M | −$19.8M |
| Dec 2021 | $1.24M | $40.7M | −$39.5M |
| Dec 2020 | $467K | $29.4M | −$28.9M |
| Dec 2019 | $213K | $22.7M | −$22.5M |
| Dec 2018 | $206K | $148M | −$148M |
| Dec 2017 | $183K | $11.7M | −$11.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.